SRTANasdaqServices-Health ServicesFiscal year ends December 31
Strata Critical Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$4.54+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $391.41M
- P/E (TTM)
- 8.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
20.9%+5.8 pts over 5 years
Operating margin
-11.3%+25.7 pts over 5 years
Net margin
21.0%+55.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +34.3% | – | +53.1% | – | |
| Gross profit | +39.0% | – | +77.6% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2019 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -41.8% | 16.5% | |
| Return on assets | – | – | 14.2% | |
| Current ratio | – | – | 6.38 | |
| Capex to revenue | – | 1.9% | 4.9% | |
| Diluted shares | – | 25M | 82M |
Where the cash went
Fiscal 2020 to 2025, five years combined
Strata Critical Medical generated $110.22M from operations and spent $43.48M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$110.22M
Used
$43.48M
Capital expenditure$43.24M99%Dividends$00%Share buybacks$244.00K1%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin21.0%
×Asset turnover0.68×
×Equity multiplier1.16×
=Return on equity, FY202516.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 21.0% | 0.68× | 1.16× | 16.5% |
| FY2024 | -18.6% | 0.53× | 1.21× | -12.0% |
| FY2021 | -79.3% | 0.28× | 1.19× | -26.5% |
| FY2020 | -43.4% | 0.16× | 9.26× | -63.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$41.35M
- Cash generatingOperating cash flow above zero-$48.91M
- Return on assets improvedROA up on the prior year-9.3% → 16.1%
- Earnings backed by cashOperating cash flow above net income-$48.91M vs $41.35M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.07 → 6.38
- No dilutionShare count did not rise77M → 82M
- Gross margin improvedGross margin up on the prior year20.15% → 20.86%
- More efficientAsset turnover rose0.50 → 0.77